Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk.
Watch the short 2 minute video below to see how to adminster Zoladex (goserelin) to your patients.
Prescribing information can be found at the top and bottom of this web page.
Request Device Training
Patient resources
1. Put the patient in a comfortable position with the upper part of the body slightly raised. Prepare the injection site according to local policy and procedure.
2. Remove the syringe from the opened foil pouch and hold the syringe at a slight angle to the light. Check that at least part of the ZOLADEX Implant is visible (Figure 1).
3. Grasp the plastic safety tab and pull away from the syringe and discard (Figure 2). Remove needle cover. Unlike liquid injections, there is no need to remove air bubbles as attempts to do so may displace the implant.
4. Holding the syringe around the protective sleeve, using an aseptic technique, pinch the patient’s skin and insert the needle at a slight angle (30 to 45 degrees) to the skin (Figure 3). With the opening of the needle facing up, insert needle into the subcutaneous tissue of the anterior abdominal wall below the navel line, until the protective sleeve touches the patient’s skin.
NOTE: The ZOLADEX syringe cannot be used for aspiration.
If the hypodermic needle penetrates a large vessel, blood will be seen instantly in the syringe chamber. If a vessel is penetrated, withdraw the needle and immediately control any resultant bleeding, monitoring the patient for signs or symptoms of abdominal haemorrhage. After ensuring the patient is haemodynamically stable another ZOLADEX implant may be injected with a new syringe elsewhere
5. Do not penetrate into muscle or peritoneum. Incorrect grip and angle of administration is shown (Figure 4).
6. Depress the plunger fully, until you can depress no more, to discharge the ZOLADEX implant and to activate the protective sleeve. You may hear a ‘click’ and will feel the protective sleeve automatically begin to slide to cover the needle. If the plunger is not depressed fully the protective sleeve will not activate.
7. Holding the syringe as shown in Figure 5, withdraw the needle and allow protective sleeve to continue to slide and cover needle.
Dispose of the syringe in an approved sharps collector.
READY-TO-USE IMPLANT OFFERING RELIABLE DELIVERY OF FULL DOSE
No refrigeration or pre-mixing required; the ZOLADEX pre-filled syringe with SafeSystem® comes ready to administer1,2
FLEXIBILITY TO DELIVER 4- OR 12-WEEKLY DOSING Available in pre-filled syringes in short-acting (3.6mg) and long-acting formulations (10.8mg) to support 4- and 12-weekly dosing, respectively
QUICK TO ADMINISTER AND ASSOCIATED WITH MINIMAL DISCOMFORT IN THE MAJORITY OF PATIENTS
In a study with blindfolded patients, a majority reported minimal pain (VAS <10 mm) from ZOLADEX (n=24) administration; in prostate cancer patients receiving two subsequent injections of Zoladex median pain scores (and range) were 5 (0-38) mm and 7 (0-51)mm. Mean administration time was <45 seconds3.
ZOLADEX SAFESYSTEM® OFFERS PROTECTION TO STAFF
Single dose SafeSystem® syringe includes a protective sleeve1,2
The majority of patients report minimal pain (VAS <10 mm)
Extra care should be taken when administering ZOLADEX to patients with a low BMI and/or receiving full anticoagulation medications.
VAS=visual analogue scale; LHRHa=Luteinizing Hormone - Releasing Hormone analogue;
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
GB-72079 | March 2026
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
